UNSPSC 51401801: Ciclotizolam

This classification denotes a benzodiazepine with the molecular formula C20H18BrClN4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JK517QTN4Q, chemically known as 2-bromo-4-(o-chlorophenyl)-9-cyclohexyl-6h-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine but generally known as ciclotizolam, which bears US NIH Compound Identifier 71949. European Medicines Agency schedules Ciclotizolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06251MIG.

UNSPSC 51401801 Ciclotizolam, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The single identifiable recent opportunity — Seminole County, Florida's IFB60459723LAS posted June 30, 2026 — solicits Naloxone and Safe Drug Deactivation Systems rather than ciclotizolam itself, suggesting either a tagging mismatch or that the code is not the active vehicle for pharmaceutical procurement in this jurisdiction. Naloxone procurement, when it does appear, targets opioid-response and community health support, typically through county health departments or emergency management offices; the Seminole County solicitation required quarterly deliveries of 1,900 units of Naloxone and 800 deactivation systems annually to the Community Health Building in Sanford, with all shipping costs vendor-borne and an initial two-year term with optional one-year renewal. No other recent state and local opportunities under this code are present in the source data.

The code shows no meaningful geographic spread or repeat-buyer pattern in recent activity. Seminole County's solicitation, posted with a response deadline of July 26, 2023 (already closed as of the current date), included standard compliance requirements — E-Verify authorization, drug-free workplace certification, workers' compensation and general liability insurance — and a three-month probationary termination clause. The procurement did not specify set-aside designations and was potentially funded through FEMA, introducing additional federal compliance obligations around environmental regulations. Given the scarcity of relevant recent opportunities, this code warrants monitoring for renewed state and local pharmaceutical or drug-response procurement rather than immediate pursuit.